OSI Pharmaceuticals Inc. is acquiring substantially all the assets of one of its subsidiaries, Prosidion Ltd., in connection with the latter's purchase of a Phase II diabetes drug and related technology. (BioWorld Today)
OSI Pharmaceuticals Inc. is acquiring substantially all the assets of one of its subsidiaries, Prosidion Ltd., in connection with the latter's purchase of a Phase II diabetes drug and related technology. (BioWorld Today)
The regulatory process for much-ballyhooed Macugen is under way.Partners Eyetech Pharmaceuticals Inc. and Pfizer Inc. completed their submission of a new drug application with the FDA, applying for use of the potential blockbuster in wet age-related macular degeneration. (BioWorld Today)
The regulatory process for much-ballyhooed Macugen is under way.Partners Eyetech Pharmaceuticals Inc. and Pfizer Inc. completed their submission of a new drug application with the FDA, applying for use of the potential blockbuster in wet age-related macular degeneration. (BioWorld Today)
